PMC:7283670 / 58718-59141 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T213","span":{"begin":205,"end":209},"obj":"Body_part"},{"id":"T214","span":{"begin":247,"end":254},"obj":"Body_part"},{"id":"T215","span":{"begin":352,"end":355},"obj":"Body_part"}],"attributes":[{"id":"A213","pred":"fma_id","subj":"T213","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A214","pred":"fma_id","subj":"T214","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A215","pred":"fma_id","subj":"T215","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T136","span":{"begin":205,"end":209},"obj":"Body_part"}],"attributes":[{"id":"A136","pred":"uberon_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T353","span":{"begin":302,"end":304},"obj":"Disease"}],"attributes":[{"id":"A353","pred":"mondo_id","subj":"T353","obj":"http://purl.obolibrary.org/obo/MONDO_0017941"}],"text":"Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T558","span":{"begin":205,"end":209},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T559","span":{"begin":205,"end":209},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T560","span":{"begin":311,"end":313},"obj":"http://purl.obolibrary.org/obo/PR_000010213"}],"text":"Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T56768","span":{"begin":247,"end":254},"obj":"Chemical"}],"attributes":[{"id":"A54910","pred":"chebi_id","subj":"T56768","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T219","span":{"begin":151,"end":156},"obj":"Phenotype"}],"attributes":[{"id":"A219","pred":"hp_id","subj":"T219","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1822","span":{"begin":236,"end":254},"obj":"Gene"},{"id":"1823","span":{"begin":256,"end":259},"obj":"Gene"},{"id":"2111","span":{"begin":151,"end":156},"obj":"Disease"}],"attributes":[{"id":"A1822","pred":"tao:has_database_id","subj":"1822","obj":"Gene:1401"},{"id":"A1823","pred":"tao:has_database_id","subj":"1823","obj":"Gene:1401"},{"id":"A2111","pred":"tao:has_database_id","subj":"2111","obj":"MESH:D005334"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage\nSecondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event"}